| 9781/13381 | US=69 / Câncer Hong D, Chintala L. Combining targeted therapies. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 361-81. ISBN 978-1-60327-423-4. COMBINANDO TERAPIAS-ALVO; TERAPIA-ALVO; TERAPIA PERSONALIZADA; VIAS DE SINALIZACAO; RESISTENCIA A DROGAS; DESENVOLVIMENTO DE DROGAS |
| 9782/13381 | US=69 / Câncer Camacho LH. Drug development in cancer medicine: challenges for targeted approaches. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 383-410. ISBN 978-1-60327-423-4. DESENVOLVIMENTO DE DROGAS EM CANCER; TERAPIA-ALVO; DESAFIOS; OBSTACULOS; DESENVOLVIMENTO DE DROGAS; ENSAIOS CLINICOS; FASE I |
| 9783/13381 | US=69 / Câncer Welsh SJ, Powis G. Toward personalized therapy for cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 411-25. ISBN 978-1-60327-423-4. TERAPIA PERSONALIZADA PARA O CANCER; CANCER; MEDICINA PERSONALIZADA; TERAPIA INDIVIDUALIZADA; FARMACOGENOMICA; TERAPIA-ALVO; ALVOS MOLECULARES |
| 9784/13381 | US=7 / Tórax Rosemberg J, Sobreiro MC. Tabagismo e doenças pulmonares. In: Tarantino AB. Doenças pulmonares. 6ª ed. Rio de Janeiro: Guanabara Koogan, 2008. p. 140-55. ISBN 85-2771333-7. DOENCAS PULMONARES; TABAGISMO; DOENCA PULMONAR OBSTRUTIVA CRONICA; BRONQUITE CRONICA; ENFISEMA PULMONAR; CANCER DE PULMAO; AGENTES CANCERIGENOS DO TABACO; ONCOGENES DO TABACO; INFECCOES PULMONARES; TUBERCULOSE; NICOTINA |
| 9785/13381 | US=58 / Câncer Dijkstra KK, Blanchetot C, Boonstra. Evasion of G1 checkpoints in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 3-26. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLE G1 EM CANCER; CICLO CELULAR; CHECKPOINT G1 CEDO; PONTO DE RESTRICAO; ESTRESSE MITOGENICA HIPER; CHECKPOINT ENERGIA; ROS |
| 9786/13381 | US=58 / Câncer Hurley PJ, Bunz F. Distinct pathways involved in s-phase checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 27-36. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLO S-CHECKPOINT; INTRA-S-FASE CHECKPOIN; CHECKPOIN REPLICACAO; S-M CHECKPOINT; ATR; CHK1; CHK2; REPLICACAO DO DNA |
| 9787/13381 | US=58 / Câncer Kuang J, Wang R. Mechanisms of G2 phase arrest in DNA damage-induced checkpoint response. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 37-51. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. G2 CHECKPOINT; CDC25; PP2A; 14-3-3; 14-3-3O; P53; P21; GADD45 |
| 9788/13381 | US=58 / Câncer Krämer A. Centrosomes in checkpoint responses. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 53-67. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CENTROSSOMAS NAS RESPOSTAS CHECKPOINT; CENTROSSOMA; DANOS NO DNA; CHECK-POINT; CHK1; PERICENTRIN; MICROCEFALINA; CDC25; SINDROME SECKEL; MICROCEFALIA; AMPLIFICACAO CENTROSSOMA; CATASTROFE MITOTICA |
| 9789/13381 | US=58 / Câncer Lee MH, Yeung SCJ, Yang HY. Interplay of 14-3-3 family of proteins with DNA damage-regulated molecules in checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 69-80. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FAMILIA DE PROTEINAS COM 14-3-3; DANOS AO DNA; RESPOSTA CHECKPOINT; 14-3-3; AKT; MDM2; P53; DANOS NO DNA |
| 9790/13381 | US=58 / Câncer Nakanishi M. Chromatin modifications and orchestration of checkpoint response in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 83-93. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. MODIFICACOES DE CROMATINA; ORQUESTRACAO DE RESPOSTA; CONTROLE EM CANCER; CHK1; CHK2; P53; REPLICACAO DO DNA |
| 9791/13381 | US=58 / Câncer Kaina B, Roos WP, Christmann M. DNA damage response and the balance between cell survival and cell death. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 95-108. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; SOBREVIVENCIA CELULAR; MORTE CELULAR; CHECKPOINTS; CICLO CELULAR; RESPOSTA A DANOS DO DNA; REPARACAO DO ADN; P53; APOPTOSE; RECEPTORES DE MORTE; FAS; CAIXA ELETRONICO; ATR; DROGAS ANTICANCER |
| 9792/13381 | US=58 / Câncer Pentimalli F, Cito L, Giordano A. Dysfunction of the RB retinoblastoma gene in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 109-22. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DISFUNCAO DO GENE; RETINOBLASTOMA RB NO CANCER; RETINOBLASTOMA; FAMILIA RB; SUPRESSORES TUMORAIS; CICLO CELULAR; G1-S DE TRANSICAO; CHECKPOINTS; E2F |
| 9793/13381 | US=58 / Câncer Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER |
| 9794/13381 | US=58 / Câncer Friedenson B. The BRCA1/2 pathway prevents some leukemias and lymphomas in addition to breast/ovarian cancers: malignancies that overcome checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 155-68. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. BRCA1; BRCA2; REPARACAO DO ADN; LEUCEMIAS; LINFOMAS; LINFOMA DE CELULAS DO MANTO; LEUCEMIA MIELOIDE AGUDA |
| 9795/13381 | US=58 / Câncer Post SM, Quinás-Cardama A, Lozano G. Regulation of p53 activity and associated checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 171-88. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P53; MDM2; P19; TUMORIGENESE; CANCER; RAS; CICLO CELULAR; RB; CICLINA; CDK |
| 9796/13381 | US=58 / Câncer Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS |
| 9797/13381 | US=58 / Câncer Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE |
| 9798/13381 | US=58 / Câncer Le XF, Bast Junior RC. p27Kip1 as a biomark and target for treatment of cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 215-33. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P27KIP1; CICLO CELULAR; SUPRESSOR DE TUMOR; TERAPIA ALVO; TRASTUZUMAB |
| 9799/13381 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 9800/13381 | US=58 / Câncer Zhang H, Xiao Z, Sowin T. ChK1 and ChK2 as checkpoint targets. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 245-59. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CHK1; CHK2; INIBIDORES; PARADA DO CICLO CELULAR; REVOGACAO DA RESPOSTA CHECKPOINT; CHEMOPROTECTION; BIOMARCADORES PREDITIVOS |